Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Overview

The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in Chinese female patients.

Full Title of Study: “A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2014

Detailed Description

Current recommended dosage of Etoposide in treating breast cancer is 50 mg/m2 orally once a day for 21 days, repeated every 28 days. With retrospective data review, this study intends to adjust Etoposide dose to 60 mg/m2 daily for 10 days, repeated every 21 days as a cycle, to investigate the effectiveness and safety of Etoposide monotherapy in the treatment of recurrent or metastatic breast cancer in Chinese female patients.

Interventions

  • Drug: Etoposide
    • Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.

Arms, Groups and Cohorts

  • Experimental: Etoposide
    • Etoposide Capsules

Clinical Trial Outcome Measures

Primary Measures

  • Progression-free survival
    • Time Frame: Up to 1 year

Secondary Measures

  • Clinical response rate
    • Time Frame: Every six weeks
    • Assessed by RECIST v1.1 criteria.
  • 1-year survival rate
    • Time Frame: Up to 1 year
  • Adverse events
    • Time Frame: Subjects will be followed from date of enrollment until the date of last visit, expected up to 1 year
  • Quality of Life
    • Time Frame: Every six weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Age: 18-80 years old. – ECOG status: 0-2. – Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer. – No more than three prior chemotherapies, adjuvant chemotherapy excluded. – Received prior anthracycline, taxane therapy. – At least 4 weeks from previous chemotherapy. – Measurable disease of >=2 cm (>=1 cm on spiral CT scan). – Life expectancy of ≥ 3 months. – Adequate organ functions: – Hemoglobin ≥10.0 g/dl, Absolute neutrophil count ≥1.5×10^9/L, Platelet count ≥100×10^9/L, – Creatinine clearance ≥60ml/min, – Bilirubin ≤1.5 times upper limit of normal (ULN); AKP,AST and ALT ≤2.5x ULN(≤5x ULN if due to liver metastases). – Signed informed consent. – Menopausal women or received surgical sterilization, women with children potential must not be pregnant or nursing with negative pregnancy test and willing to practice acceptable methods of birth control during the study and 3 months after the study. Exclusion Criteria:

  • Pregnancy or lactation. – Untreated or uncontrolled CNS metastases, or with refractory psychiatric illness. – Prior treatment with Etoposide. – Other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer. – Clinically significant heart diseases (e.g.congestive heart failure, symptomatic coronary disease, uncontrolled cardiac arrhythmia, Myocardial infarction) within the past 12 months. – Serious uncontrolled concurrent infection or metabolism disorder. – Concurrent treatment for active peptic ulcer disease or with digestive disorders. – Prior radiotherapy and major surgery within 3 weeks before screening. – Less than 4 weeks since prior investigational agents. – Metastases present in more than one-third whole liver. – Unable or unwilling to comply with the study protocol. – Unsuitable to participate in study, that in the opinion of the treating physician.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chinese Academy of Medical Sciences
  • Collaborator
    • Peking University Cancer Hospital & Institute
  • Provider of Information About this Clinical Study
    • Principal Investigator: Binghe Xu, Deputy Director of Department of Medical Oncology – Chinese Academy of Medical Sciences
  • Overall Official(s)
    • Binghe Xu, M.D., Ph.D, Principal Investigator, Chinese Academy of Medical Sciences
  • Overall Contact(s)
    • Peng Yuan, M.D., 86-10-8778-8114, yuanpeng01@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.